Earlier this month, CorVent received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the RESPOND-19 Ventilator. In addition, the company stated they anticipate full FDA clearance of the system and CE Mark for European market access in 2021.


About CorVent Medical, Inc.

CorVent Medical, a privately held portfolio company of medtech incubator Coridea LLC, is committed to developing smart, versatile, lifesaving ventilators for critical care. The company's first product, the RESPOND-19™ Ventilator, provides lifesaving respiratory support designed for reliable and affordable deployment during surges in demand and times of greatest need. Optimized for multiple patient use, the streamlined system enables sophisticated ventilation with excellent infection control. The RESPOND-19 Ventilator recently received FDA Emergency Use Authorization (EUA) and is currently available for commercial use.


About Siemens Healthineers
Siemens Healthineers is shaping the future of HealthCare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients.


SOURCE CorVent Medical, Inc.

Back to HCB News

U.S. Healthcare Homepage